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Abstract
Background: The prevalence of chronic kidney disease (CKD) is increasing worldwide and in Africa. Health related
quality of life (QOL) has become an essential outcome measure for patients with CKD and end stage renal disease
(ESRD). There is growing interest worldwide in QOL of CKD patients but paucity of data in Ghana. This study sought
to assess QOL in patients with moderate to advanced CKD (not on dialysis) and establish its determinants.
Methods: We conducted a cross sectional observational study at the renal outpatient clinic at Komfo Anokye
Teaching Hospital (KATH). We collected demographic, clinical and laboratory data. A pretested self-administered
Research and Development corporation (RAND®) 36-Item Health Survey questionnaire was administered and QOL
scores in physical component summary (PCS) and mental component summary (MCS) were computed. Determinants of
QOL were established by simple and multiple linear regression. P value of < 0.05 was considered statistically significant.
Results: The study included 202 patients with CKD not on dialysis. There were 118(58.5%) males. Mean age was 46.7 ± 16.
2 years. The majority, 165(81.7%) of patients were on monthly salaries of less than GHS 500 (~USD 125). Chronic
glomerulonephritis was the most common cause of CKD in 118 (58.5%) patients followed by diabetes mellitus in 40
(19.8%) patients and hypertension in 19 (9.4%) patients. The median serum creatinine was 634.2 μmol/L (IQR 333–1248)
and the median eGFR was 7ml/min/1.73m2 (IQR 3–16). The most common stage was CKD stage 5 accounting for 143
(71.1%), followed by CKD stage 4 with 45 (22.4%) of cases and 13 (6.5%) of CKD stage 3. The overall mean QOL score
was 40.3 ± 15.4. MCS score was significantly lower than PCS score (37.3 ± 10.8 versus 43.3 ± 21.6, P < 0.001). Multiple
linear regression showed that low monthly income (p = 0.002) and low haemoglobin levels (p = 0.003) were predictive
of overall mean QOL.
Conclusion: Patients with moderate to advanced CKD had low-income status, presented with advanced disease and
had poor QOL. Anaemia and low-income status were significantly associated with poor QOL.
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Background
The prevalence of chronic kidney disease (CKD) is increas-
ing worldwide and in Africa [1, 2]. The global prevalence is
estimated to be 10–13% [1, 3]. The prevalence of CKD in
sub-Saharan Africa was found to be 13.9% in a meta-ana-
lysis [4]. Chronic glomerulonephritis together with
non-communicable diseases such as hypertension and
diabetes mellitus account for the increasing prevalence of
CKD in Sub-Saharan Africa and in Ghana [5]. CKD is asso-
ciated with increasing morbidity and mortality and also
known to impact negatively on quality of life (QOL) [6, 7].
QOL is defined by the World Health Organisation
(WHO) as “an individual’s perception of their position in
life in the context of the culture and value system where
they live, and in relation to their goals, expectations,
standards, and concerns” [8]. It is a comparison between
patients’ expectations and reality. QOL also reflects
treatment quality in patients with CKD and end stage
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renal disease (ESRD) since adapting to CKD involves
physical, psychological and social processes to achieve
the best outcomes [9]. QOL also represents a functional
impact of a disease or its treatment on the subjective
feeling of the affected individual about their physical,
mental, spiritual, emotional, social and functional
wellbeing [10]. The collection of QOL data helps
patients understand their disease and the implications of
treatment on their health [11].
Progression to ESRD also serves as an important burden
on health care systems [12]. Management of ESRD involves
haemodialysis (HD), peritoneal dialysis (PD), renal trans-
plantation and conservative management. Conservative
management is now established as a treatment option
among geriatric patients in some developed countries [13].
In Ghana, like most countries in Sub-Saharan Africa,
most patients with ESRD cannot afford renal replace-
ment therapy (RRT). There is lack of governmental sup-
port for chronic dialysis and most patients have to pay
out of pocket to survive. Ghana has a national health in-
surance scheme that covers some medical conditions
but not chronic haemodialysis. In most cases, patients
and their relatives may need to solicit for funds from
their families, community, corporate organizations and
religious groups to enable them go through with their
haemodialysis sessions and plan renal transplantation
outside the country as Ghana currently does not have a
renal transplant programme. The social support system
for patients with CKD is mainly by their families,
community, work place and religious groups.
In majority of cases, conservative management is not
the patient’s choice as seen in developed countries. When
conservation management is resorted to in Ghana, medi-
cations are prescribed to make patients comfortable both
on admission and after discharge from hospital. They are
extensively counselled about end of life decisions. Pallia-
tive care is not free in Ghana. Patients and or their fam-
ilies have to pay for palliative care and treatments if
medications or procedures performed are not covered by
the national health insurance scheme. This worsened the
financial burden on patients and in some situations, they
just request to be discharged home against medical advice.
Haemodialysis, which is the most common form of
RRT in Ghana, only provides a partial solution to the
deteriorating kidney function. Patients still have to deal
with some symptoms of the disease, many medications,
a strict diet, regular hospital visits, multiple admissions
and changes in body image when dialysis catheters are
inserted or arteriovenous fistulae are made.
With many patients with ESRD unlikely to gain access
to RRT in Ghana mainly because of financial constraints,
it is imperative to ensure that CKD patients with ad-
vanced disease have the best QOL when being managed.
There has been growing interest lately in improving the
QOL of patients with kidney disease worldwide and not
just on survival [14–16] but very few studies have focused
on QOL of patients with CKD and ESRD in Ghana.
We therefore set out to establish the QOL of patients
with moderate to advanced CKD in Ghana and determine
the predictors of QOL. This will aid in the holistic man-
agement of patients with CKD and ESRD more especially
in the absence of RRT. It will serve as the baseline data for
further QOL studies in patients on RRT in Ghana.
Methods
We conducted a cross sectional study at renal out-patient
clinic of the Komfo Anokye Teaching Hospital (KATH).
KATH is a 1200 bed capacity tertiary level health facility
located in Kumasi in the Ashanti region of Ghana. KATH
runs a twice-a-week out-patients’ clinic for patients with
CKD and ESRD. Due to poor economic status, most pa-
tients seen are unable to afford RRT and are managed
conservatively even in ESRD with indications for haemo-
dialysis. Haemodialysis is the main RRT modality in
Ghana. Ghana does not have a renal transplant program
and does not offer peritoneal dialysis as a treatment
modality for adult patients with ESRD. The study was
conducted from October 2016 to August 2017.
Participants were included in the study if they had
confirmed CKD with estimated glomerular filtration rate
(eGFR) of less than 60 ml/min/1.73m2 as estimated by
the Modification of Diet in Renal Disease (MDRD) equa-
tion [17] and gave a written informed consent. They
were then staged according to Kidney Disease Outcomes
Quality Initiative (KDOQI) [18] and Kidney Disease Im-
proving Global Outcome (KDIGO) criteria [19]. Patients
with acute kidney injury, on RRT or with concurrent
chronic illness such as malignancy, chronic liver disease
or stroke unrelated to the CKD or admitted to hospital
within the last 1 month were excluded from the study.
The clinical aetiology of CKD as diagnosed by the
attending nephrologist was recorded from clinical notes.
A structured questionnaire was administered to each
patient to obtain the following data: age, sex, level of edu-
cation, marital status, occupation and monthly salary in
Ghanaian Cedis (GHS). Clinical and laboratory data such
as blood pressure, haemoglobin level, mean corpuscular
volume (MCV), mean corpuscular haemoglobin (MCH),
serum urea and serum creatinine were also recorded.
Anaemia was defined as haemoglobin level of less than
12 g/dl as suggested by the KDIGO guidelines [19]. Partic-
ipants were then required to complete a pre-tested, vali-
dated, structured and a self-administered RAND 36-Item
Health Survey (Version 1.0) [20]. The Short Form (SF-36)
scoring system has been widely used and validated in most
European countries. It was developed in the United States
during the medical outcome survey between 1985 and
1992 and has been translated into 55 languages [21]. The
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questionnaire includes eight concepts: physical function-
ing, bodily pain, role limitations due to physical health
problems, role limitations due to personal or emotional
problems, emotional well-being, social functioning, en-
ergy/fatigue, and general health perceptions. It also in-
cludes a single item that provides an indication of
perceived change in health. Scores range from 0 to 100
with 100 representing the best QOL score and zero repre-
senting the worst QOL scores.
Data was entered into a Microsoft software Excel® 2016
by a data entry clerk. The data was then cleaned and
backed-up onto an external drive. Double entry was done
to ensure the quality of the data obtained. Data collected
was then exported into the statistical package Stata® ver-
sion 13 [22]. Descriptive analysis was performed as means
± standard deviations if data is normally distributed and
medians and inter-quartile ranges if data was not normally
distributed. Percentages and frequencies were used to
describe variables where appropriate.
Chi square test was used for comparisons between
groups with categorical variables and an unpaired Stu-
dent t test was used to compare groups with normally
distributed continuous variables and Mann Whitney U
test when not normally distributed. Simple and multiple
linear regression analysis were then performed on the
physical component summary (PCS) scores and the
mental component summary (MCS) scores for determi-
nants of QOL. Statistically significant variables identified
in the simple linear regression were then included in a
multiple linear regression model to establish the
independent predictors for the QOL among patients
with moderate to advanced CKD. Statistical significance
was set at a two tailed p-value of less than 0.05.
Ethical approval from the Committee on Human Re-
search, Publications and Ethics (CHRPE), Kwame Nkru-
mah University of Science and Technology and KATH
was obtained before the commencement of the study.
Results
The study included 202 patients with moderate to ad-
vanced CKD not on dialysis. There were 118 (58.4%) males.
The mean age of participants was 46.7 ± 16.2 years.
Ninety-six (47.5%) of patients were fully employed and 83
(41.1%) were unemployed. Majority, 176 (87.1%) did not
attain tertiary level of education. The vast majority, 165
(81.7%) of patients were on monthly salaries of less than
GHS 500 (~USD 120). Socio-demographic data of partici-
pants are shown in Table 1. The most common cause of
CKD was chronic glomerulonephritis accounting for 118
(58.4%) of patients followed by diabetes mellitus in 40
(19.8%) patients and hypertension in 19 (9.4%) patients.
The most common stage of presentation of CKD was stage
5 with eGFR of less than 15ml/min/1.73m2 accounting for
143 (71.1%) of the cases. The median eGFR at presentation
was 7ml/min/1.73m2 (IQR 3–16). Most, 187(92.6%) of pa-
tients had hypertension. The mean haemoglobin level was
9.2 ± 2.5 g/dl. All as shown in Table 1.
The most commonly used antihypertensive class was
calcium channel blockers used by 161 (80.1%) of patients
and diuretics used by 160 (79.6%) of patients. Only 19
(9.4%) of patients with moderate to advanced CKD were
on subcutaneous erythropoietin and 4 (2%) were on
intravenous iron preparations. All as shown in Table 1.
The overall mean QOL score was 40.3 ± 15.4. Mean
mental component summary (MCS) score (37.3 ± 10.8,
95% CI [35.8–38.8]) was significantly lower than the
mean physical component summary (PCS) scores (43.3
± 21.6, 95% CI [40.3–46.3], P < 0.001). The scores for the
various sub-domain are shown in Table 2.
Patients with low monthly income less than GHS 500
(~USD 125) had a significantly lower overall mean
QOL score than those with higher monthly income
above GHS 500 (38.5 ± 14.1 versus 48.4 ± 18.3, p <
0.001). Patients with anaemia also had a significantly
lower overall mean QOL score as compared to those
with haemoglobin levels greater than 12 g/dl (38.3 ±
13.6 versus 49.2 ± 19.3, p < 0.001). Patients with low
mean corpuscular volume (MCV) had a significantly
lower overall mean QOL score 36.9 ± 10.7 as compared
to those with normal or high MCV (42.8 ± 17.7, p =
0.007). Patients with CKD stage 5 also had a signifi-
cantly lower overall mean QOL score as compared to
those presenting with CKD stages 3 and 4 (37.9 ± 13.6
versus 46.4 ± 17.9, p < 0.001). Patients with serum urea
greater than 20 mmol/L as compared to those with urea
less than 20 mmol/L also had significantly lower overall
mean QOL scores (36.1 ± 13.1 versus 44.0 ± 16.7, p =
0.004). All as shown in Table 3.
Linear regression analysis
In simple linear regression, PCS scores were associated
with low monthly income status (p < 0.001), low haemo-
globin (p < 0.001), low MCV (0.019), serum urea > 20
mmol/L (p < 0.001) and CKD stage 5 (p < 0.001). All as
shown in Table 4.
Simple linear regression analysis of mental compo-
nent summary scores were associated with low
monthly income status (p = 0.002), CKD stage 5 (p =
0.009), low haemoglobin levels (p < 0.001), low MCV
(p = 0.037) serum urea > 20 mmol/L (p = 0.015) and
the use of IV iron preparation (p = 0.009) as shown
in Table 5.
Simple linear regression of the overall QOL scores
showed low haemoglobin level (P < 0.001), low MCV
(0.0179), uraemia (p < 0.001), low monthly income status
(p = 0.004) and CKD stage 5 (P = 0.003) as significant
determinants as shown in Table 6.
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Multiple linear regression analysis
Multiple linear regression analysis showed that low
monthly income status (p = 0.002) and haemoglobin
levels were significant predictors of mean PCS scores.
Multiple linear regression revealed the predictors of
mean MCS scores as low monthly income status (p =
0.004), low haemoglobin (p = 0.025) and the use of intra-
venous iron preparation (p = 0.001). Predictors of overall
mean QOL score were low-income status (p = 0.002)
and low haemoglobin level (p = 0.003) in multiple linear
regression all as shown in Table 7.
Discussion
To our knowledge, this is the first ever study to assess the
quality of life among patients with moderate to advanced
CKD not on dialysis using the RAND® 36-Item Health
Survey questionnaire in Ghana. Our study showed that
the QOL of patients with moderate to advanced CKD was
poor. Low-income status, anaemia and CKD stage 5 were
identified to be significantly associated with poor QOL.
There was a slight predominance of males over females
as shown in other studies [23, 24]. Male gender has been
associated with faster progression of renal disease as com-
pared to females [25]. Worse progression of CKD in males
have also been validated in a meta-analysis of eight studies
involving 2229 patients [24]. The mean age in our cohort
Table 1 Characteristics of patients with moderate to advanced
chronic kidney disease at Komfo Anokye Teaching Hospital n =
202
Characteristic n = 202
Age (yrs) μ SD 46.7 ± 16.2
Male Gender n (%) 118 (58.4%)
Marital status
Married n (%) 137 (67.8)
Single n (%) 42 (20.8)
Divorced/separated n (%) 12 (5.9)
Widowed n (%) 11(5.5)
Educational level
No formal education n (%) 22 (10.9)
Primary education n (%) 21 (10.4)
Junior high school n (%) 56 (22.7)
Senior high school n (%) 77 (38.1)
Tertiary n (%) 26 (12.9)
Employment status
Full time employment n (%) 96 (47.5)
Part time employment n (%) 4 (2.0)
Unemployed n (%) 83 (41.1)
In training n (%) 4 (2.0)
Retired n (%) 15 (7.4)
Monthly income status
Less than GHS 500 n (%) 165 (81.7)
GHS 500–1499 n (%) 20 (9.9)
GHS 1500–2499 n (%) 9 (4.5)
GHS 2500–3499 n (%) 2 (1.0)
Greater than GHS 3500 n (%) 6 (3.0)
Cause of CKD
Chronic glomerulonephritis n (%) 118 (58.4)
Diabetes mellitus n (%) 40 (19.8)
Hypertension n (%) 19 (9.4)
Polycystic kidney disease n (%) 14 (6.9)
HIVAN n (%) 5 (2.5)
Obstructive uropathy n (%) 2 (1.0)
Others n (%) 4 (2.0)
Stage of CKD
Stage 3 n (%) 13 (6.5)
Stage 4 n (%) 45 (22.4)
Stage 5 n (%) 143 (71.1)
Systolic BP mmHg μ SD 152.3 ± 30.0
Diastolic BP mmHg μ SD 88.6 ± 19.8
Hypertension n (%) 187 (92.6)
Laboratory characteristics
Haemoglobin levels (g/dL)) μ SD 9.2 ± 2.5
Table 1 Characteristics of patients with moderate to advanced
chronic kidney disease at Komfo Anokye Teaching Hospital n =
202 (Continued)
Characteristic n = 202
Anaemia (Hb < 12 g/dL) n (%) 164 (81.2)
MCV fL μ SD 81.4 ± 7.6
MCH pg/cell μ SD 28.0 ± 3.2
Serum Urea mmol/L M (IQR) 19.2 (12.5–30.5)
Serum Creatinine umol/L M (IQR)) 634.2 (333–1248)
GFR ml/min/1.73m2 M (IQR) 7 (3–16)
Medications used
ACEi/ARBs n (%) 141 (70.2)
Calcium channel blockers n (%) 161 (80.1)
Diuretics n (%) 160 (79.6)
Beta- blockers n (%) 56 (27.9)
Hydralazine n (%) 56 (27.9)
Methyldopa n (%) 80 (39.8)
ESA n (%) 19 (9.4)
Intravenous iron n (%) 4 (2.0)
Yrs years, SD standard deviation, μ mean, n. number, GHS Ghanaian cedis, USD
United States dollars, MCV mean corpuscular volume, MCH mean corpuscular
haemoglobin, SD standard deviation, μ mean, IQR interquartile range, M
median, BP blood pressure, GFR glomerular filtration rate, fL femtolitres, pg
pigogram, CKD chronic kidney disease, HIVAN human immunodeficiency virus
associated nephropathy, ACEi angiotension converting enzyme inhibitor, ARBs
angiotensin II receptor blocker, ESA erythropoietin stimulating agent, others
chronic schistosomiasis and posttraumatic nephrectomy
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was 46 years similar to an earlier study in Ghana [23] but
lower than shown in the meta-analysis with a mean age of
48.1 years [24]. The mean age of CKD patients in devel-
oped countries has been shown however to be higher than
50 years in most studies [26–28].
The overall mean QOL score in patients with moder-
ate to advanced CKD not on dialysis in our cohort was
lower as compared to a study by Perlman et al. [29].
This may be due to low median eGFR of 7 ml/min/
1.73m2 in our patients as compared to 23ml/min/
1.73m2 in their study. The QOL scores were low for
both physical component summary (PCS) and mental
component summary (MCS) scores. MCS scores were
significantly lower than PCS (37.3 versus 43.3; p <
0.001). This may be due to the greater impact of the dis-
ease burden on the mental status of patients that may be
overlooked by attending physicians and nephrologists in
most cases. Management of patients with CKD by their
physicians mainly focus on making patients physically
healthy with less emphasis on the mental and psycho-
logical impact of the disease on their general wellbeing.
Focus on the mental health of patients with CKD may
therefore be necessary to improve their QOL. It has
been shown that the psychological impact of chronic
diseases including CKD is underestimated by health care
workers and patients relatives [11].
Low-income status was identified as a predictor of poor
QOL as also shown in other studies [30, 31]. Most pa-
tients with CKD were of low monthly income status about
or just minimally higher the minimum wage currently in
Ghana. Over 80% of patients were on a monthly income
of less than GHS 500 (USD 125). The minimum wage in
Ghana is currently pegged at GHS 8.8 (∼USD 2.2) per day
with a monthly income of about USD 66 [32]. Further-
more, majority (87.1%) of patient’s did not get to tertiary
level academically. These patients may therefore lack the
requisite knowledge in the prevention and early manage-
ment of CKD. Patients with CKD also have poor health
seeking behaviour due to their low-income status and low
literacy rate. They therefore present late with very
advanced CKD as shown in our study. Patients with CKD
are also unable to afford the cost of management of CKD
and RRT when they progress to ESRD due to their low
socioeconomic status [33]. The cost of haemodialysis in
Ghana is currently between GHS190 to 260 (~USD 50–
65) per session. The cost of chronic haemodialysis is not
covered by the national health insurance scheme (NHIS).
Practically, the NHIS only pays for acute haemodialysis in
Table 2 Quality of life scores for physical component summary
and mental component summary and their subdomains of
patients with CKD n = 202
Principal domains Sub-domain Mean (SD) Total
mean (SD)
Physical health 44.8 ± 30.0
Role physical 12.4 ± 33.0
Bodily pain 59.2 ± 29.0




Role emotional 12.4 ± 33.0








Overall mean Quality of
life score
40.3 ± 15.4
Table 3 Independent variables and their association with the
overall mean quality of life among patients with moderate to
advanced chronic kidney disease n = 202
Variable Mean ± SD Frequency P value
Age (yrs) ≥50 39.8 ± 15.5 93 0.687
Age (yrs) < 50 40.7 ± 15.4 109
Female gender 38.9 ± 14.2 84 0.268
Male gender 41.3 ± 16.2 118
Above JHS 41.1 ± 16.2 103 0.486
JHS and below 39.5 ± 14.5 99
Employed 39.9 ± 15.9 100 0.673
Unemployed 40.8 ± 15.0 102
Monthly income(GHS) < 500 38.5 ± 14.1 165 < 0.001
Monthly income(GHS)≥ 500 48.4 ± 18.3 37
Married 41.0 ± 15.6 137 0.373
Unmarried 38.9 ± 15.0 65
Haemoglobin < 12 g/dL 38.3 ± 13.6 164 < 0.001
Haemoglobin level≥ 12 g/dL 49.2 ± 19.3 38
MCV < 80 fL 36.9 ± 10.7 85 0.007
MCV≥ 80 fL 42.8 ± 17.7 117
MCH < 27 pg/cell 39.9 ± 14.4 62 0.783
MCH≥ 27 pg/cell 40.5 ± 15.9 140
CKD stage 5 37.9 ± 13.6 143 < 0.001
CKD Stage 3 and 4 46.4 ± 17.9 58
Serum urea≥20mmol/L 36.1 ± 13.1 90 0.004
Serum urea < 20 mmol/L 44.0 ± 16.7 101
ESA use 41.9 ± 12.9 19 0.651
Not on ESA 40.2 ± 15.7 182
IV iron use 50.4 ± 19.6 4 0.191
No IV iron 40.2 ± 15.3 197
JHS junior high school, MCV mean corpuscular volume, MCH mean corpuscular
haemoglobin, GHS Ghana Cedis, CKD chronic kidney disease, ESA
erythropoietin stimulating agent, IV intravenous, SD standard deviation
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very few situations (if any), up to GHS 850 (∼USD 265)
[33] irrespective of the number of sessions required for re-
covery. Patients are also required to buy their medications
such as anti-hypertensives, haematinics, intravenous iron
preparations and subcutaneous erythropoietin stimulation
agents (ESA) and carry out routine laboratory investiga-
tions to assess their response to treatment. Patients’
inability to afford treatment especially for anaemia may
negatively affect their QOL as shown in our study.
Prevalence of anaemia among our patients with mod-
erate to advanced CKD was 81.2% as shown in other
studies [23, 34]. Anaemia is a common presentation in
patients with CKD and progressively worsens with ad-
vancing renal disease. Most patients had normocytic
normochromic anemia which has been described as the
characteristic form of anaemia in renal disease due to
decreased production of erythropoietin since 1950 [35].
Lately, increase in hepcidin as a result of chronic inflam-
mation has been described in the pathogenesis of
anaemia in patients with CKD [36]. Forty-two percent of
patients presented however with low MCV anaemia
which may have resulted from anorexia [37], occult
gastrointestinal bleeding, iron deficiency or the presence
of hepcidin causing anaemia of chronic disease [36].
Table 4 Simple linear regression analysis of physical component summary scores in patients with moderate to advanced chronic
kidney disease n = 202
Variable Coefficient Standard error t 95% CI P value
Age −0.02 0.09 −0.25 − 0.21–0.16 0.806
Educational level 1.61 3.04 0.53 −4.38–7.60 0.597
Employment status −1.23 3.04 −0.40 −7.22–4.77 0.687
Low income −13.61 3.81 −3.57 −21.13–−6.09 < 0.001
Marital status 3.49 3.24 1.07 −2.91–9.90 0.284
Hypertension −5.35 3.28 −1.63 −11.81–1.11 0.104
Hemoglobin 2.97 0.57 5.23 1.85–4.09 < 0.001
MCV 0.46 0.19 2.36 0.07–0.85 0.019
MCH 0.67 0.48 1.40 − 0.27–1.61 0.163
Uraemia −11.87 3.04 −3.89 −17.89–−5.86 < 0.001
CKD stage 5 −12.63 3.25 −3.88 −19.04–−6.22 < 0.001
ESA use 3.03 5.21 0.58 −7.24–13.30 0.561
IV Iron use 6.25 10.91 0.57 −15.27–27.77 0.567
MCV mean corpuscular volume, MCH mean corpuscular haemoglobin, CKD 5 chronic kidney disease with GFR < 15ml/min/1.73m2, ESA erythropoietin stimulating
agent, IV intravenous, CI confidence interval, uraemia serum urea > 20 mmol/L
Table 5 Simple linear regression analysis of mental component summary scores in patients with moderate and advanced chronic
kidney disease n = 202
Variable Coefficient Standard error t 95% confidence interval P value
Age −0.01 0.05 −0.01 − 0.93–0.09 0.995
Educational level 1.42 1.51 0.94 − 1.56–4.41 0.348
Employment status −0.61 1.51 −0.40 −3.60–2.38 0.690
Low income −6.08 1.91 −3.18 −9.84–−2.30 0.002
Marital status 0.66 1.62 0.41 −2.54–3.86 0.685
Hypertension −1.70 1.64 −1.03 −4.93–1.54 0.303
Hemoglobin 1.15 0.29 3.95 0.57–1.72 < 0.001
MCV 0.21 0.10 2.10 0.01–0.40 0.037
MCH 0.32 0.24 1.35 −0.15–0.80 0.178
Uraemia −3.78 1.55 −2.45 −6.83–−0.73 0.015
CKD stage 5 −4.36 1.65 −2.64 −7.62–1.10 0.009
ESA use 0.34 2.60 .0.13 −4.76–5.48 0.895
IV Iron 14.12 5.35 2.64 3.56–24.69 0.009
MCV mean corpuscular volume, MCH mean corpuscular haemoglobin, CKD 5 chronic kidney disease with GFR < 15ml/min/1.73m2, ESA erythropoietin stimulating
agent, IV intravenous, CI confidence interval, uraemia serum urea > 20 mmol/L
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Anaemia could also be due to low red cell survival
which has also been reported in patients with CKD
[37]. Iron absorption is poor in patients with CKD
making intravenous iron more beneficial in improving
iron status in patients with kidney disease but most
patients with moderate to advanced CKD cannot
afford intravenous iron preparations. Anaemia could
also be due to chronic bleeding from uraemia
associated platelet dysfunction and frequent phlebot-
omy [37].
Table 6 Simple linear regression analysis of independent variables of overall mean quality of life score in patients with chronic
kidney disease n = 202
Variable Coefficient Standard error t 95% confidence interval P value
Age − 0.01 0.07 0.86 −0.14–−0.12 0.862
Educational level 1.52 2.17 0.70 −2.76–5.80 0.486
Employment status −0.92 2.17 −0.42 −5.20–3.37 0.673
Low income −0.84 2.72 −3.62 −15.21–4.48 < 0.001
Marital status 2.07 2.32 0.89 −2.50–6.65 0.373
Hypertension −3.52 2.34 −1.50 −8.14–1.10 0.134
Hemoglobin 2.06 0.41 5.06 1.26–2.86 < 0.001
MCV 0.34 0.14 2.39 0.06–0.62 0.018
MCH 0.50 0.34 1.45 −0.18–1.17 0.148
Uraemia −7.83 2.19 −3.58 −12.15–−3.51 < 0.001
CKD stage 5 −8.50 2.33 −3.64 −13.10–−3.90 < 0.001
ESA use 1.69 3.72 0.45 −5.65–9.03 0.650
IV Iron 10.19 7.77 1.31 −5.13–25.51 0.191
MCV mean corpuscular volume, MCH mean corpuscular haemoglobin, CKD 5 chronic kidney disease with GFR < 15ml/min/1.73 m2, ESA erythropoietin stimulating
agent, IV intravenous, uraemia urea> 20 mmol/L
Table 7 Multiple linear regression analysis of independent variables for physical, mental component summary and overall QOL
scores in patients with CKD
Variable Beta coeff Standard error t 95% CI P value
Physical component Summary score Adjusted R2 = 0.18
Low income −0.21 3.52 −3.18 −19.69–−4.62 0.002
CKD stage 5 −0.07 3.97 −0.93 −11.53–4.13 0.352
haemoglobin 0.24 0.67 3.13 0.77–3.4 0.002
MCV 0.77 0.20 1.12 −0.17–0.61 0.264
uraemia −0.13 3.33 −1.73 −12.31–0.81 0.209
Mental Component summary Score Adjusted R2 = 0.15
Low income −0.20 1.94 −2.91 −9.47–−1.81 0.004
CKD stage 5 −0.04 2.02 −0.41 −4.82–3.14 0.689
haemoglobin 0.18 0.34 2.26 −0.10–1.43 0.025
MCV 0.13 0.10 1.82 −0.02–0.38 0.070
uraemia −0.09 1.70 −1.13 −5.27–1.44 0.261
IV iron use 0.23 5.13 3.30 6.81–27.04 0.001
Overall QOL Score Adjusted R2 = 0.17
Low income −0.21 2.75 −3.16 −14.11–−3.27 0.002
CKD stage 5 −0.07 2.86 −0.85 −8.05–3.22 0.398
haemoglobin 0.24 0.48 3.02 0.50–2.40 0.003
MCV 0.09 0.14 1.27 −0.10–0.46 0.205
uraemia −0.11 2.39 −1.49 −8.28–1.16 0.138
MCV mean corpuscular volume, CKD 5 chronic kidney disease with GFR < 15ml/min/1.73 m2, IV intravenous, SD standard deviation, QOL quality of life, CI
confident interval, uraemia serum urea> 20 mmol/L, coeff coefficient
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Unfortunately, only 9% of the patients in our cohort were
on ESA. This is because most of the patients are of low so-
cioeconomic status and cannot afford the ESA. ESA is
therefore less prescribed by attending physicians and ne-
phrologists. ESAs have been used over the years with many
benefits in improving symptoms, avoiding frequent haemo-
transfusions and to prevent complications associated with
transfusions like iron overload, infections and transfusion
related reactions [38–40]. ESA has been shown to be asso-
ciated with hypertension, increased thrombosis and malig-
nancies [41]. ESA use with haemoglobin target levels
beyond 13 g/dL has not been shown to be beneficial and
even associated with poorer outcomes in major studies [19,
39]. Anorexia in patients with CKD and vomiting associ-
ated with uraemia also leads to decreased intake and
absorption of iron from the gut. Intravenous iron is war-
ranted in some cases but the use of intravenous iron was
also low due to its high cost and under-prescription by at-
tending physicians. Only 4% patients in our cohort were on
intravenous iron preparations.
Patients with haemoglobin levels less than 12 g/dl had
poorer QOL as compared to patients without anaemia
(38.3 ± 13.6 versus 49.2 ± 19.3; p < 0.001). Anemia has
been shown in several studies to be associated with ad-
verse clinical outcome [34] and affects QOL in patients
with CKD [42, 43]. Anaemia was found to predict poor
PCS scores, MCS scores and the overall mean QOL
scores in multiple linear regression analysis as also
shown in other studies in both developing and devel-
oped countries [44–46].
Low MCV was significantly associated with mean MCS
scores (p = 0.037), PCS scores (0.019) and overall mean
QOL (p = 0.018). This may be related to iron deficiency,
which may have resulted from anorexia, occult blood loss
from uraemic gastritis or bleeding diathesis from dysfunc-
tional platelets seen in patients with CKD [37]. Low MCV
was however insignificant in a multiple linear regression
analysis for PCS, MCS scores and overall mean QOL
scores and not a predictor of poor QOL.
The use of IV iron preparation was found to be signifi-
cantly associated with MCS scores but not overall mean
QOL or PCS scores. This may be because those who
could afford IV iron were mainly of high-income status,
which may have positively affected their MCS scores.
The number of patients on intravenous iron prepara-
tions was however very small.
Majority (71%) of patients had CKD stage 5 as also
shown in some studies in Africa [23, 47]. Patients
reporting late with CKD stage 5 also had a poorer QOL
as compared to those reporting with CKD stages 3 and
4. This may be because patients with CKD stage 5
present with more symptoms, greater disease burden
and had significantly lower haemoglobin levels (8.4 ver-
sus 11.1, P < 0.001). Symptoms of uraemia such as
anorexia, nausea and vomiting may have also contrib-
uted to their poor QOL.
QOL was however not associated with age, gender, edu-
cational status, employment status, marital status and
mean corpuscular haemoglobin (MCH) in our cohort
similar to that found by Suet et al. [48] who found no as-
sociation with age and marital status. This differed from
another study that found an association with age, gender
and race [49]. Male gender, Asian ethnicity and poor nu-
tritional status were found to be associated with poor
QOL in another study [50]. Czyzewski et al. showed that
increasing age, increased body mass index and unemploy-
ment were associated with lower QOL scores [51]. Pa-
tients with higher socioeconomic status, male gender and
unmarried were shown by Alveres et al. in a large multi
center study of over 3000 participants in Brazil to be asso-
ciated with improved quality of life scores [31].
Our study had a number of limitations. Iron studies
were not assessed due to financial constraints. Iron stud-
ies would have helped identify clearly if iron deficiency
was the cause of the low MCV. The RAND® 36-Item
questionnaire [20] was interpreted to few participants
who could not read nor write. This may have introduced
interviewer bias because the tool was supposed to be a
self-administered questionnaire. It was also a tertiary
hospital based study were the worst of cases are referred
to very late. This may have led to selection bias in their
poorer outcomes.
Conclusions
The overall QOL in patients with moderate to advanced
CKD was poor. MCS score was significantly poorer than
PCS scores. Determinants of poor QOL were low economic
status, patients with CKD stage 5 and anaemia. There is the
need for governmental support for patients with CKD to
improve their QOL. QOL assessment should be introduced
for routine clinical review to identify those with poor QOL
for proper management based on the determinants of poor
QOL. A psychologist and or psychiatrists should be
involved in the management of patients with moderate to
advanced CKD to focus on mental components that affects
the QOL to improve the overall health of patients with
moderate to advanced CKD in Ghana.
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